The Center for Alternatives to Animal Testing is an academic center affiliated with the Division of Toxicological Sciences in the Department of Environmental Health Sciences of the Johns Hopkins University Bloomberg School of Public Health.

 

Johns Hopkins School of Public Health

DNT2 logo

Creating a Humane and Efficient Approach to Developmental Neurotoxicity Testing

November 12-14, 2008
Reston, Virginia, USA

Program Schedule and Information

Image of neurons

PDF Brochure available for download and distribution

MAIN PAGE

REGISTRATION INFORMATION

Tuesday, November 11

5:30–7:30 Registration with Reception

Wednesday, November 12

8:00-9:00 Registration and Continental Breakfast

9:00-9:15 Welcome
Alan M. Goldberg, PhD

Objectives of Conference (Powerpoint)
David E. Owen, PhD

PLENARY
Chair: Gihan I. Tennekoon, MD

9:15-10:00 Toxicity Testing in the 21st Century: Promises and Conundrums (Powerpoint)
Kim Boekelheide, MD, PhD

10:00-10:45 Adverse Neurodevelopmental Outcome—The Role for In Vitro (Powerpoint)
Cynthia F. Bearer, MD, PhD

10:45-11:15 Refreshment Break

11:15-12:00 Criteria
Kevin M. Crofton, PhD

12:00-1:00 Lunch

ENDPOINTS
Chair: Stanley Barone, Jr., PhD

1:00-2:15 Endpoint One—Proliferation,
Differentiation, Migration and Apoptosis (Powerpoint)
Ellen Fritsche, PhD

2:15-3:30 Endpoint Two—Neuronal Connectivity Including Neurite Outgrowth, Synapse Formation and Function (Neurochemical and Electrophysiological) (Powerpoint)
William R. Mundy, PhD

3:30-4:00 Refreshment Break

4:00-5:15 Endpoint Three—Glial (Function) Including
Migration, Myelination, Inflammation and Signaling (Powerpoint)
Joseph P. Bressler, PhD

CRITERIA

5:15-6:00 Discussion and Re-examination of Criteria (Powerpoint)
Kevin M. Crofton, PhD

6:00-7:00 Reception

Thursday, November 13

8:00-8:30 Continental Breakfast

PLENARY
Chair: Holger Knaut, PhD

8:30-9:15 Models: Cell Cultures (Powerpoint)
Lucio G. Costa, PhD

9:15-10:00 Models: Non-Mammalian (Powerpoint)
Pamela J. Lein, PhD

10:00-10:30 Refreshment Break

10:30-12:30 CONCURRENT BREAKOUT GROUPS

Group 1: Cell Culture
Chair: Marc Willuhn, PhD
Rapporteur: Abby A. Li, PhD
(Powerpoint, Excel document)

Invited Poster Presentations

Group 2: Models
Chair: Robert L. Tanguay, PhD
Rapporteur: Stephanie Padilla, PhD

Invited Poster Presentations

12:30-1:30 Lunch

1:30-2:15 SUMMARIES OF BREAKOUT GROUPS
Chair: Anna Price, PhD

Group 1: Cell Culture (Powerpoint)
Abby A. Li, PhD

Group 2: Models (Powerpoint)
Stephanie Padilla, PhD

DATA INTERPRETATION, INTEGRATION/USE, AND POLICY
Chair: Martin L. Stephens, PhD

2:15-3:00 Developing Predictive Bioactivity Signatures from ToxCast’s High Throughput Screening Data (Powerpoint)
Robert J. Kavlock, PhD

3:00-3:30 Refreshment Break

3:30-4:00 The Use of In Vitro Data in Understanding Human Health Effects and Risk (Powerpoint)
James S. Bus, PhD

4:00-5:30 OVERVIEW TO DECISION MAKING WITH DNT DATA
Chair: Tina E. Levine, PhD

Opening Statement and Charge to the Panel
Paul A. Locke, JD, DrPH

Panel: Melvin E. Andersen, PhD
Thomas Hartung, MD, PhD
Abby A. Li, PhD (Powerpoint)
Elise Miller, MEd
Catherine Willett, PhD

• Data needs
• Levels of decision making
>> Product development
>> Hazard assessment
>> Regulatory applications

5:30-8:30 Posters and Vendor Exhibits
Reception and Buffet Dinner

Friday, November 14

8:00-8:30 Continental Breakfast

MEETING THE OBJECTIVES OF THE CONFERENCE

8:30-10:30 Policy Framework (Powerpoint)

Chair: Philip G. Lewis, MD, MPH
Panel: Charles Hastings, PhD
Robert J. Kavlock, PhD
Paul A. Locke, JD, DrPH (Powerpoint)
David E. Owen, PhD
David E. Ray, PhD
Ellen K. Silbergeld, PhD

Applying DNT Data

• Prioritization for further action
• Using alternative data in conjunction with other data (e.g. animals and humans)
• Using alternative data when other data are not available

10:30-11:00 Refreshment Break

11:00-12:15 Biology Framework

Opening Remarks on Goals of Session (Powerpoint)
Kevin M. Crofton, PhD

Panel: Lucio G. Costa, PhD, ATS
Holger Knaut. PhD
Pamela J. Lein, PhD
Sue Marty, PhD

• Criteria for evaluating alternative methods (codify criteria— which are most important?)
• What assays are ready now? Or where should we invest current efforts? Review of data presented at meeting.
• Critical research needs to move forward (endpoints, models, methods, new biology)

12:15-12:30 SUMMARY AND FINAL COMMENTS FROM THE AUDIENCE
Philip G. Lewis, MD, MPH

Close

12:30 Lunch